Obesity: Current Treatment and Future Horizons

Area of Science:

• Metabolic disorders
• Pharmacology
• Endocrinology

Background:

• Obesity prevalence has nearly doubled globally in under 35 years, causing significant health and economic burdens.
• Obesity leads to widespread physiological dysfunction and multiple comorbidities.
• Current FDA-approved long-term obesity treatments remain limited to five medications.

Purpose of the Study:

• To review current and emerging therapeutic strategies for obesity treatment.
• To focus on novel molecular targets that have advanced to clinical trials.
• To explore the potential of white adipose tissue browning and Aldh1a1 inhibitors.

Main Methods:

• Literature review of scientific publications and clinical trial data.
• Analysis of novel drug targets and mechanisms of action for obesity.
• Discussion of emerging therapeutic approaches including diacylglycerol O-acyltransferase-1 inhibitors, growth hormone secretagogue receptor-1a antagonists/inverse agonists, melanocortin-3 receptor agonists, and melanin-concentrating hormone receptor-1 antagonists.

Main Results:

• Several novel molecular targets are under investigation for obesity treatment.
• Specific drug candidates have progressed to clinical trials, indicating therapeutic potential.
• The 'browning' of white adipose tissue and the inhibition of Aldh1a1 present promising new avenues.

Conclusions:

• Despite the escalating obesity epidemic, therapeutic options are scarce.
• Emerging drug targets and strategies, including adipose tissue manipulation, offer hope for more effective obesity management.
• Further research and clinical trials are crucial to validate these novel approaches.